- Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study
Y Suzuki et al, 2021, Acta Gastro Enterologica Belgica CrossRef - Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
Michitaka Imai et al, 2021, European Journal of Gastroenterology & Hepatology CrossRef - Predictors of tolvaptan short‐term response in patients with refractory ascites: A meta‐analysis
Ioannis Bellos et al, 2020, Journal of Gastroenterology and Hepatology CrossRef - Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
Shunsuke Shiba et al, 2020, BMC Gastroenterology CrossRef - Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis
Masato Nakai et al, 2018, Hepatology Research CrossRef - Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial
Jieting Tang et al, 2020, BMC Gastroenterology CrossRef - Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites
Tomomi Kogiso et al, 2017, Hepatology Research CrossRef - Predictors of the Response to Tolvaptan Therapy and Its Effect on Prognosis in Cirrhotic Patients with Ascites
Tomomi Kogiso et al, 2017, Ascites - Physiopathology, Treatment, Complications and Prognosis CrossRef